CME: secondary brain cancer, metastatic BC imaging

Overview
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.00.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Carey Anders, MD, FASCO
Medical Director
Duke University
Durham, NC
Dr. Anders has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, AstraZeneca, Elucida, Caris, Incyclix, Beigene
Royalties: UpToDate, Jones and Bartlett
Consulting Fees: Genentech, Eisai, IPSEN, Seattle Genetics, AstraZeneca, Novartis, Immunomedics, Elucida, Athenex, Roche
Sarah Sammons, MD
Senior Physician
Dana-Farber Cancer Institute
Boston, MA
Dr. Sammons has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: AstraZeneca, Eli Lilly, Relay, SEAGEN, Sermonix
Consulting Fees: Foundation of Medicine, AstraZeneca, Daiichi Sankyo, Eli Lilly, Pfizer, Incyclix, Relay, Gilead, Sermonix
Reviewers/Content Planners/Authors:
- Tim Person has no relevant relationships to disclose.
- Wilma Guerra has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe the key differentiating factors that drive efficacy and safety of HER2-targeted agents in combination regimens for advanced HER2-expressing breast cancer.
- Evaluate key data on HER2-targeted combination regimens to guide evidence-based, guideline-concordant selection and sequencing of optimal second-line and subsequent therapies for metastatic HER2-expressing breast cancer.
- Develop strategies to identify, treat, and mitigate the burden of brain metastases in patients with HER2-expressing breast cancer.
- Assess emerging data evaluating HER2-targeted agents in the treatment of HER2-expressing breast cancer.
Target Audience
This activity has been designed to meet the educational needs of medical oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with HER2-Expressing MBC.
Accreditation Statement
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation Statement
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 contact hour(s)/0.10 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-021-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit(s). Approval is valid until 6/30/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc. and Pfizer Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 02/06/2025
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.